Can Cardio Firms Curb M&A? Selective Seeding Is Combo Product Strategy
This article was originally published in The Gray Sheet
Executive Summary
Large cardiovascular device firms maintain they will exercise discipline in forming strategic alliances with biotech and IT companies, although such deals are considered key to sustainable growth
You may also be interested in...
Acquisition Criteria Remain Conservative For Large Cardiovascular Firms
Boston Scientific, Guidant and St. Jude Medical business development chiefs are reluctant to consider technologies outside their firms' core strengths when weighing potential acquisitions
Acquisition Criteria Remain Conservative For Large Cardiovascular Firms
Boston Scientific, Guidant and St. Jude Medical business development chiefs are reluctant to consider technologies outside their firms' core strengths when weighing potential acquisitions
Medtronic Biotech Presence: “Pawn Or Rook?” Is VP Oesterle’s Challenge
Biologics delivery to aid organ restoration is a frontier that will permit Medtronic to advance beyond its core strengths in electromechanical implants, according to Senior VP-Medicine & Technology Stephen Oesterle